HER2阳性乳腺癌
HER2+ 疾病
HER2+ 状态与疾病更具侵犯性和更差的预后相关
HER2+乳腺癌是一种更具侵犯性的疾病类型 1-3
HER2 过度表达与肿瘤转移和血管新生的增加相关 4
HER2+ 疾病患者，疾病复发的风险更高，生存预后更差1, 5
增加淋巴结阴性肿瘤的风险
在一项针对淋巴结阴性浸润性乳腺癌的回顾性研究中，HER2基因增强与早期复发和疾病相关的死亡高度相关 6
* 基于324 例淋巴结阴性乳腺癌标本档案，患者仅接受手术治疗。疾病早期复发(n=242 例) 定义为诊断后24个月内出现复发. 疾病相关的死亡，观察到232例患者明确死于疾病，或者至少随访了36个月的患者。†微小肿瘤定义为直径 ≤ 1.0 cm; 大肿瘤定义为直径 >1.0
- HER2 基因扩增时导致HER2持续过度表达的潜在生物学变化 7
- HER2 过度表达在疾病病程中持续，并驱动肿瘤生长7-9
增加激素受体阳性(HR+) 肿瘤的风险 10
- HER2 过度表达预示着激素受体阳性乳腺癌患者的不良预后
- 数据来源于Gago等人2005年的一项临床研究, HER2+ 肿瘤与HER2-者相比，无疾病进展生存期 (DFS) (P<0.001) 更短，总生存期(OS) (P=0.001)方面也是如此
研究设计: 该项回顾性临床研究纳入了516例既往患有原发性I期或II期乳腺癌患者，其中180例 HR+ 患者. 所有患者接受了他莫昔芬单药或化疗联合他莫昔芬治疗.随访5-10年(平均7.3年). 使用免疫组化来检测患者的蛋白表达。
References:
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science. 1987; 235:177-182.
2. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. JClin Oncol.1990;8:103-112.
3. Ross JS, Fletcher JA.HER-2/neu (c-erb-B2) gene and protein in breast cancer. AmJClin Pathol.1999;112(suppl 1):S53-S67.
4. Niu G, Carter WB. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways. Cancer Res. 2007; 67:1487-1493.
5. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. JPathol. 2003; 200: 290-297.
6. Press MF, Bernstein L, Thomas PA, et al.HER-2/neu gene amplification characterized by fluorescence in situhybridization: poor prognosis in node-negative breast carcinomas. JClin Oncol.1997;15: 2894-2904.
7. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol.2000;27(suppl 9):13-19.
8. Simon R, Nocito A, Hubscher T, et al. Patterns of Her-2/neu amplification and overexpression in primary and metastatic breast cancer. JNatl Cancer Inst. 2001;93:1141-1146.
9. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999; 26(suppl 12):60-70.
10. Gago EE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone-receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy. JSteroid Biochem Mol Biol.2006; 98:36-40.